The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 28, No. 7, pp. 925-939.
© 1994 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wintermeyer, S.
Right arrow Articles by Kyllonen, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wintermeyer, S.
Right arrow Articles by Kyllonen, K.


Research Articles

Whole-cell and acellular pertussis vaccines

SM Wintermeyer, MC Nahata, and KS Kyllonen

OBJECTIVE: To provide a review of pertussis vaccines, including information on efficacy, adverse reactions, and antibody production following administration of both whole-cell and acellular pertussis vaccines. DATA SOURCES: A MEDLINE search and extensive review of journals was conducted to identify the information for this review. DATA EXTRACTION: Pertinent studies reporting experience with pertussis vaccinations were reviewed. DATA SYNTHESIS: The differences in efficacy, adverse reactions, and antibody responses between whole-cell and acellular pertussis vaccines are emphasized. The status of acellular pertussis vaccination in the US is defined. CONCLUSIONS: Acellular (chemically detoxified or recombinant) pertussis vaccine formulation appears to cause fewer adverse reactions than whole-cell vaccine in most studies. Clinical efficacy and safety in the very young has not been well established. Thus, acellular pertussis vaccine is reserved for the 4th and 5th doses in the US. Oral or intranasal formulations of the pertussis vaccine are being evaluated.


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
J. Manley and A. Taddio
Acetaminophen and Ibuprofen for Prevention of Adverse Reactions Associated with Childhood Immunization
Ann. Pharmacother., July 1, 2007; 41(7): 1227 - 1232.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
H. J. Vosper
Pediatric Immunization: Current Recommendations and Controversies
Journal of Pharmacy Practice, February 1, 1996; 9(1): 14 - 26.
[Abstract] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1994 by Harvey Whitney Books Company.